PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 2, 2021
ApiJect Appoints New Leadership Advisory Board
Author(s)Pharmaceutical Technology Editors
The new board will join the company’s co-founder and chairman, Jay Walker, and company CEO, Franco Negron.
Advertisement
ApiJect Systems, an injectable technology company, announced on Jan. 28, 2021 that it has appointed a new Leadership Advisory Board to join the company’s co-founder and chairman, Jay Walker, and company CEO, Franco Negron.
"ApiJect is indeed privileged to welcome its first members of our Leadership Advisory Board,” Negron said in a company press release. “We see this board as an essential part of our company's mission to be world leaders in the technological advancement of injectable devices. These are individuals who dream big and seek aggressive change in global and US public health."
The Leadership Advisory Board members include:
- Professor Heidi J. Larson, PhD, director of The Vaccine Confidence Project, professor of Anthropology, Risk, and Decision Science, London School of Hygiene and Tropical Medicine; clinical professor, Global Health, University of Washington, Seattle, WA
- Dr. Regina M. Benjamin, MD, family physician founder of Bayou La Batre Rural Health Clinic
- Dr. Edward Kelley, chief global health officer for ApiJect Research Foundation
- Dr. Michael J. Free, OBE, former vice-president for Technology at PATH
- Rueben M. Stokes, former vice president of Global Diversity and Inclusion for Thermo Fisher Scientific, and former corporate senior executive in Diversity, Equity, and Inclusion
- Dr. Marietta Vázquez, MD, professor, Yale University School of Medicine, attending, Yale Pediatric Primary Care Center.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Successful Internal Audit Planning and Execution
5